SlideShare a Scribd company logo
Huateng Pharma https://en.huatengsci.com
Antibody-Drug Conjugates for
Cancer Therapy - Prospects and
Challenges
Antibody-drug conjugates (ADCs) are a rapidly evolving class of anticancer
therapeutics consisting of antibodies attached to potent cytotoxic drugs via
chemical linkers. The antibodies are designed to target specific antigens
(receptors) highly expressed in tumor cells. ADCs provide highly selective drugs
to tumors, thus minimizing their systemic exposure and potentially leading to
improved therapeutic indices (higher efficacy and fewer adverse effects). Most
ADCs follow a similar mechanism of action involving antibody-mediated
receptor binding, ADC internalization and subsequent release of payload and
cytotoxicity, as shown in Figure 1.The success of ADCs relies on several key
factors as belows.
1) Target antigens (e.g. CD30, HER2, CD22, CD33, CD79b, Nectin 4, Trop2,
BCMA, CD19)
2) Antibody type (e.g. IgG1, IgG2, IgG4, nanobodies, bispecific antibodies)
3) Payload type (e.g. Monomethyl auristatin E (MMAE), DM4, calicheamycin,
DM1, MMAF)
4) Linker type (e.g. valine-citrulline, Sulfo-SPDB, hydrazone linker)
5) Conjugation platform (e.g. lysine-, cysteine- and site-specific conjugation)
6) Target indications (e.g. breast cancer, lymphoma, leukemia, uroepithelial
cancer, lung cancer, ovarian cancer).
ADCs mechanism of action, image source: reference 1
Huateng Pharma https://en.huatengsci.com
FDA Approved ADCs
To date, 11 ADCs have been approved by the FDA, namely Adcetris®,
Kadcyla®, Besponsa®, Mylotarg®, Lumoxiti®, Polivy®, Padcev®, Enhertu®,
Trodelvy®, Blenrep® and Zynlonta™, for oncology indications only (Table 1,
Figure 2a). In addition, more than 80 ADCs are currently in clinical studies as
single agents or in combination for various tumor types.
FDA Approved ADCs, Image
source: https://www.biochempeg.com/article/202.html
Two of the latest ADCs to be approved, Trodelvy and Zynlonta, were
developed with PEG moiety as part of their linker technology to
improve solubility and stability in vivo.
On April 23, 2021, the FDA approved Zynlonta, the first CD19-targeted ADC,
for the treatment of adults with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL), based on the pivotal Phase II clinical trial LOTIS-2.
Zynlonta (loncastuximab tesirine) is a humanized CD19 monoclonal antibody
conjugated to pyrrolobenzodiazepine (PBD) dimeric cytotoxin via a linker.
PEG linker for Zynlonta: Mal-NH-PEG8-COOH
Huateng Pharma https://en.huatengsci.com
Structure of Zynlonta
On April 22,2020, the FDA approved sacituzumab govitecan (Trodelvy), a
Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38), for
the treatment of some patients with triple-negative breast cancer.
PEG linker for Trodelvy: 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid
Structure of Trodelvy
Novel ADCs in clinical trials
More than 80 ADCs are currently in active clinical trials, with the majority in
Phase I and Phase I/II (Table 2, Figure 3a). More than 80% of clinical trials are
investigating the safety and efficacy of ADCs in a variety of solid tumors, while
the remaining trials involve hematologic malignancies (Figure 3b). This may
indicate a shift in experimental ADCs in solid tumors in recent years with the
early success of T-DM1 and the recent approval of T-Dxd, sacituzumab
govitecan, and enfortumab vedotin. In this list, there are about 40 different
targets with several ADCs against the same target (Table 2, Figure 3c).
Huateng Pharma https://en.huatengsci.com
ADCs in clinical trials, image source: reference 1
Challenges in the development of ADCs
Why have more not already been approved? The issue of toxicity has been a
challenge, as has the complexity of ADCs and the consequent manufacturing
challenges.
Crafting the right molecule
Finding the right targets, proteins, linkers and payloads all belong to the
discovery phase. This phase is very challenging because properly defining a
drug is key to bringing it successfully to the clinic. ADCs represent an equally
highly complex and unpredictable product class. Finding the right target and
crafting a potent molecule has proven to be much more difficult than many
researchers expected at the start of an ADC study. The initial understanding was
that finding a good target antigen for an ADC-based compound required a target
that could be rapidly internalized once it reached the cell, with the result that in
many cases, targets that were ineffective against monoclonal antibody (mAb)
therapies due to rapid internalization became the perfect targets for ADC
therapies.
Site-specific conjugation
Huateng Pharma https://en.huatengsci.com
Site-specific conjugation is considered as a second generation ADC conjugation
technique. Many ADCs in preclinical and clinical stages are based on site-specific
conjugation technology of one form or another.
Even though more site-selective ADCs are expected in the future, stochastic
conjugation of ADCs can still be successful. Site-selective conjugation does not
appear to exhibit significant differences in clinical activity and safety compared
to classical non-site-selective conjugation. The lack of commercially available
site-specific conjugated molecules is simply a consequence of the head start
that stochastic conjugation has had, but it is also possible that the simplicity of
manufacturing and the homogeneity of analytical testing methods do not
directly lead to better outcomes for patients.
Linker chemistry matters
Linker chemistry is an important component of ADCs and has a major impact on
performance. Linker chemistry plays a key role in in-vivo stability, but was
initially assumed to have a passive role with the exception of either being stable
or labile in the acidic cytosolic cellular environment.
Over the past 20 years, the technology has evolved and matured to the point
where linker technology is stable and molecules in development exhibit low
levels of de-conjugation in patients. Both protease-cleavable and non-cleavable
linkers are in development and on the market.
Classical conjugation chemistry approaches include maleimide and
hydroxysuccinamide-ester moieties (Seattle Genetics, Roche and Pfizer). There
are also a variety of newer linker technologies, some in the proof-of-concept
stage and some already in preclinical evaluation.
Undesired immune responses
ADCs are designed to be more selective than traditional chemotherapeutic
agents. The mAb are able to target cancer (or other disease) cells, with
payloads delivered with high selectivity and reduced systemic toxicity compared
to standard chemotherapeutic agents.
Unfortunately, undesired immune responses pose a problem that is difficult to
overcome. These responses are largely due to the large number of variables
being studied and the relatively small number of clinical trials being conducted.
Lower-than-expected therapeutic window
The main issue affecting ADC approvals today is that the therapeutic window for
these therapies is lower than expected. However, this window has proven to be
much more complex than originally hoped, and therefore its clinical impact is
Huateng Pharma https://en.huatengsci.com
not as great as originally thought. The complexity of ADCs themselves is also a
major issue here.
Complex supply chain
The ADC supply chain is also very complex. ADCs are unique in that they are
manufactured as a amalgamation of classical small molecule manufacturing and
traditional mAb manufacturing, with the added complexity of high potency drug
manufacturing. All three of these characteristics are complex in themselves,
and combining them brings the complexity to an even higher level. Supply chain
management of ADCs is one of the most complex processes in the
pharmaceutical industry and must be managed by experienced teams with the
lowest possible risk.
As more ADCs are approved commercially, it is believed that a roadmap will be
established for other companies to follow, leading to more success in the near
future.
References:
1. Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates:
Promises and challenges. MAbs. 2021 Jan-Dec;13(1):1951427. doi:
10.1080/19420862.2021.1951427. PMID: 34291723.

More Related Content

What's hot

Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy
ManingcinaSephe
 
Download Global cancer immunotoxins market & clinical pipeline insight 2020
Download Global cancer immunotoxins market & clinical pipeline insight 2020Download Global cancer immunotoxins market & clinical pipeline insight 2020
Download Global cancer immunotoxins market & clinical pipeline insight 2020
KuicK Research
 
Antibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysisAntibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysis
KuicK Research
 
Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next level	Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next level
Company Spotlight
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
DoriaFang
 
Global cancer immunotherapy market outlook 2020
Global cancer immunotherapy market outlook 2020Global cancer immunotherapy market outlook 2020
Global cancer immunotherapy market outlook 2020
KuicK Research
 
Inmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliadaInmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliada
Alberto IC
 
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Fundación Ramón Areces
 
Drug delivery carrier
Drug delivery carrierDrug delivery carrier
Drug delivery carrier
EchoHan4
 
Nivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCNivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCC
Abdelrahman Labban
 
1 s2.0-s0169409 x14001690-main
1 s2.0-s0169409 x14001690-main1 s2.0-s0169409 x14001690-main
1 s2.0-s0169409 x14001690-main
microbiologia.dad
 
Targeting the cancer cell
Targeting the cancer cellTargeting the cancer cell
Targeting the cancer cell
EchoHan4
 
Long acting pe gylated interferon application of peg
Long acting pe gylated interferon application of pegLong acting pe gylated interferon application of peg
Long acting pe gylated interferon application of peg
DoriaFang
 
Mechanism of Action (MoAs) for Therapeutic Antibodies
Mechanism of Action (MoAs) for Therapeutic AntibodiesMechanism of Action (MoAs) for Therapeutic Antibodies
Mechanism of Action (MoAs) for Therapeutic Antibodies
EchoHan4
 
Anti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overviewAnti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overview
DoriaFang
 
July 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy updateJuly 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy update
Yujia Sun
 
magil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complex
magil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complexmagil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complex
magil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complex
Julia Adam
 

What's hot (17)

Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy Combating drug resistance in anticancer therapy
Combating drug resistance in anticancer therapy
 
Download Global cancer immunotoxins market & clinical pipeline insight 2020
Download Global cancer immunotoxins market & clinical pipeline insight 2020Download Global cancer immunotoxins market & clinical pipeline insight 2020
Download Global cancer immunotoxins market & clinical pipeline insight 2020
 
Antibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysisAntibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysis
 
Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next level	Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next level
 
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
Fda approves besremi (ropeginterferon alfa 2b-njft) for treating polycythemia...
 
Global cancer immunotherapy market outlook 2020
Global cancer immunotherapy market outlook 2020Global cancer immunotherapy market outlook 2020
Global cancer immunotherapy market outlook 2020
 
Inmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliadaInmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliada
 
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
 
Drug delivery carrier
Drug delivery carrierDrug delivery carrier
Drug delivery carrier
 
Nivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCCNivolumab vs Docetaxel in Lung SCC
Nivolumab vs Docetaxel in Lung SCC
 
1 s2.0-s0169409 x14001690-main
1 s2.0-s0169409 x14001690-main1 s2.0-s0169409 x14001690-main
1 s2.0-s0169409 x14001690-main
 
Targeting the cancer cell
Targeting the cancer cellTargeting the cancer cell
Targeting the cancer cell
 
Long acting pe gylated interferon application of peg
Long acting pe gylated interferon application of pegLong acting pe gylated interferon application of peg
Long acting pe gylated interferon application of peg
 
Mechanism of Action (MoAs) for Therapeutic Antibodies
Mechanism of Action (MoAs) for Therapeutic AntibodiesMechanism of Action (MoAs) for Therapeutic Antibodies
Mechanism of Action (MoAs) for Therapeutic Antibodies
 
Anti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overviewAnti cancer peptide drug conjugates (pd cs) an overview
Anti cancer peptide drug conjugates (pd cs) an overview
 
July 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy updateJuly 2015 Cancer immunotherapy update
July 2015 Cancer immunotherapy update
 
magil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complex
magil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complexmagil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complex
magil_sg_adam_jd_et_al_-_development_of_a_biopharm_aceutical_is_complex
 

Similar to Antibody drug conjugates for cancer therapy - prospects and challenges htp

Maytansinoids as Payloads of ADCs DM1, DM4.pdf
Maytansinoids as Payloads of ADCs DM1, DM4.pdfMaytansinoids as Payloads of ADCs DM1, DM4.pdf
Maytansinoids as Payloads of ADCs DM1, DM4.pdf
DoriaFang
 
9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf
9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf
9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf
DoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
 
Global antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewGlobal antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-review
EchoHan4
 
Global ADC Clinical Trial Review
Global ADC Clinical Trial ReviewGlobal ADC Clinical Trial Review
Global ADC Clinical Trial Review
Creative Biolabs
 
A Brief Guide to Antibody-drug Conjugate
A Brief Guide to Antibody-drug ConjugateA Brief Guide to Antibody-drug Conjugate
A Brief Guide to Antibody-drug Conjugate
Cecilia Cummings
 
A Comprehensive Guide to ADC Payload Classes.pdf
A Comprehensive Guide to ADC Payload Classes.pdfA Comprehensive Guide to ADC Payload Classes.pdf
A Comprehensive Guide to ADC Payload Classes.pdf
DoriaFang
 
Global cancer antibody drug conjugates market and pipeline insight 2022
Global cancer antibody drug conjugates market and pipeline insight 2022Global cancer antibody drug conjugates market and pipeline insight 2022
Global cancer antibody drug conjugates market and pipeline insight 2022
KuicK Research
 
What is ADC? - Creative Biolabs
What is ADC? - Creative BiolabsWhat is ADC? - Creative Biolabs
What is ADC? - Creative Biolabs
Creative-Biolabs
 
Peptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdf
Peptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdfPeptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdf
Peptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdf
DoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
DoriaFang
 
OPRD manuscript final published copy
OPRD manuscript final published copyOPRD manuscript final published copy
OPRD manuscript final published copy
David Jackson
 
MedImmune Industrial Placement Student Programme 2016
MedImmune Industrial Placement Student Programme 2016MedImmune Industrial Placement Student Programme 2016
MedImmune Industrial Placement Student Programme 2016
Jonathan Duckworth
 
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
DoriaFang
 
Biomissiles-ADC Drugs-202205.pptx
Biomissiles-ADC Drugs-202205.pptxBiomissiles-ADC Drugs-202205.pptx
Biomissiles-ADC Drugs-202205.pptx
KrystalBeily
 
Antibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysisAntibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysis
Rajesh Sarma
 
Download Antibody drug conjugate market opportunity analysis
Download Antibody drug conjugate market opportunity analysisDownload Antibody drug conjugate market opportunity analysis
Download Antibody drug conjugate market opportunity analysis
KuicK Research
 
ADCs, A Highly Targeted Drug Therapy For Cancer
ADCs, A Highly Targeted Drug Therapy For CancerADCs, A Highly Targeted Drug Therapy For Cancer
ADCs, A Highly Targeted Drug Therapy For Cancer
DoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
DoriaFang
 
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
EduConnections
 

Similar to Antibody drug conjugates for cancer therapy - prospects and challenges htp (20)

Maytansinoids as Payloads of ADCs DM1, DM4.pdf
Maytansinoids as Payloads of ADCs DM1, DM4.pdfMaytansinoids as Payloads of ADCs DM1, DM4.pdf
Maytansinoids as Payloads of ADCs DM1, DM4.pdf
 
9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf
9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf
9 Types of Drug Conjugates Overview ADC、RDC、ISAC、SMDC、AOC.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Global antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-reviewGlobal antibody-drug-conjugate-adc-clinical-trial-review
Global antibody-drug-conjugate-adc-clinical-trial-review
 
Global ADC Clinical Trial Review
Global ADC Clinical Trial ReviewGlobal ADC Clinical Trial Review
Global ADC Clinical Trial Review
 
A Brief Guide to Antibody-drug Conjugate
A Brief Guide to Antibody-drug ConjugateA Brief Guide to Antibody-drug Conjugate
A Brief Guide to Antibody-drug Conjugate
 
A Comprehensive Guide to ADC Payload Classes.pdf
A Comprehensive Guide to ADC Payload Classes.pdfA Comprehensive Guide to ADC Payload Classes.pdf
A Comprehensive Guide to ADC Payload Classes.pdf
 
Global cancer antibody drug conjugates market and pipeline insight 2022
Global cancer antibody drug conjugates market and pipeline insight 2022Global cancer antibody drug conjugates market and pipeline insight 2022
Global cancer antibody drug conjugates market and pipeline insight 2022
 
What is ADC? - Creative Biolabs
What is ADC? - Creative BiolabsWhat is ADC? - Creative Biolabs
What is ADC? - Creative Biolabs
 
Peptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdf
Peptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdfPeptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdf
Peptide Drug Conjugates (PDCs) Novel Targeted Therapeutics For Cancer.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
OPRD manuscript final published copy
OPRD manuscript final published copyOPRD manuscript final published copy
OPRD manuscript final published copy
 
MedImmune Industrial Placement Student Programme 2016
MedImmune Industrial Placement Student Programme 2016MedImmune Industrial Placement Student Programme 2016
MedImmune Industrial Placement Student Programme 2016
 
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
Therapeutic Antibody Derivatives Antibody Conjugates & Multispecific Antibodi...
 
Biomissiles-ADC Drugs-202205.pptx
Biomissiles-ADC Drugs-202205.pptxBiomissiles-ADC Drugs-202205.pptx
Biomissiles-ADC Drugs-202205.pptx
 
Antibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysisAntibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysis
 
Download Antibody drug conjugate market opportunity analysis
Download Antibody drug conjugate market opportunity analysisDownload Antibody drug conjugate market opportunity analysis
Download Antibody drug conjugate market opportunity analysis
 
ADCs, A Highly Targeted Drug Therapy For Cancer
ADCs, A Highly Targeted Drug Therapy For CancerADCs, A Highly Targeted Drug Therapy For Cancer
ADCs, A Highly Targeted Drug Therapy For Cancer
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
Antisense Oligonucleotides, Aptamers & Triple Helix: Speech by Michael L Rior...
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
DoriaFang
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
DoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
DoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
DoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
DoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
DoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
DoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
DoriaFang
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
DoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
DoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
DoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
DoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
DoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
DoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
DoriaFang
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
DoriaFang
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
DoriaFang
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
DoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
 
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdfAptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
Aptamer-Drug Conjugate (ApDC) Current Research Progress.pdf
 

Recently uploaded

Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates
Family/Indoor Entertainment Centers Market: Regulation and Compliance UpdatesFamily/Indoor Entertainment Centers Market: Regulation and Compliance Updates
Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates
AishwaryaDoiphode3
 
Cracking the Customer Experience Code.pptx
Cracking the Customer Experience Code.pptxCracking the Customer Experience Code.pptx
Cracking the Customer Experience Code.pptx
Workforce Group
 
Top Digital Marketing Strategy in 2024.pdf
Top Digital Marketing Strategy in 2024.pdfTop Digital Marketing Strategy in 2024.pdf
Top Digital Marketing Strategy in 2024.pdf
Top IT Marketing
 
NewBase 05 July 2024 Energy News issue - 1736 by Khaled Al Awadi_compresse...
NewBase   05 July 2024  Energy News issue - 1736 by Khaled Al Awadi_compresse...NewBase   05 July 2024  Energy News issue - 1736 by Khaled Al Awadi_compresse...
NewBase 05 July 2024 Energy News issue - 1736 by Khaled Al Awadi_compresse...
Khaled Al Awadi
 
Importance of Quality Transformations in VUCA World
Importance of Quality Transformations in VUCA WorldImportance of Quality Transformations in VUCA World
Importance of Quality Transformations in VUCA World
Ankur860831
 
Best Practices in Negotiation for Business Management Students
Best Practices in Negotiation for Business Management StudentsBest Practices in Negotiation for Business Management Students
Best Practices in Negotiation for Business Management Students
zoyaws1
 
brojjeddah Home Services Company in Saudi Arabia
brojjeddah Home Services Company in Saudi Arabiabrojjeddah Home Services Company in Saudi Arabia
brojjeddah Home Services Company in Saudi Arabia
brojjeddah
 
TALENT ACQUISITION AND MANAGEMENT LECTURE 2
TALENT ACQUISITION AND MANAGEMENT LECTURE 2TALENT ACQUISITION AND MANAGEMENT LECTURE 2
TALENT ACQUISITION AND MANAGEMENT LECTURE 2
projectseasy
 
What is Venture Client for Startup entrepreneur
What is Venture Client for Startup entrepreneurWhat is Venture Client for Startup entrepreneur
What is Venture Client for Startup entrepreneur
Gokul Rangarajan
 
Entrepreneurial mindset: An Introduction to Entrepreneurship
Entrepreneurial mindset: An Introduction to EntrepreneurshipEntrepreneurial mindset: An Introduction to Entrepreneurship
Entrepreneurial mindset: An Introduction to Entrepreneurship
Sanjay Joshi
 
The-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptx
The-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptxThe-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptx
The-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptx
Jindal Global University, Sonipat Haryana 131001
 
1234567891011121314151617181920212223242
12345678910111213141516171819202122232421234567891011121314151617181920212223242
1234567891011121314151617181920212223242
fauzanal343
 
High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...
High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...
High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...
dimplekumaridk322
 
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual TrainingpptxYou Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
Cynthia Clay
 
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital  BankingCheslyn Jacobs- TymeBank: Building Consumer Trust in Digital  Banking
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
itnewsafrica
 
Cryptocurrency KYC Policies: Comparing Binance KYC Bypass with Rivals
Cryptocurrency KYC Policies: Comparing Binance KYC Bypass with RivalsCryptocurrency KYC Policies: Comparing Binance KYC Bypass with Rivals
Cryptocurrency KYC Policies: Comparing Binance KYC Bypass with Rivals
Any kyc Account
 
Pricing sophistication - auto insurance telematics
Pricing sophistication - auto insurance telematicsPricing sophistication - auto insurance telematics
Pricing sophistication - auto insurance telematics
Matteo Carbone
 
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
APKs Pure
 
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
projectseasy
 
Transforming the Future of Limo Services.pptx
Transforming the Future of Limo Services.pptxTransforming the Future of Limo Services.pptx
Transforming the Future of Limo Services.pptx
limocaptaincom
 

Recently uploaded (20)

Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates
Family/Indoor Entertainment Centers Market: Regulation and Compliance UpdatesFamily/Indoor Entertainment Centers Market: Regulation and Compliance Updates
Family/Indoor Entertainment Centers Market: Regulation and Compliance Updates
 
Cracking the Customer Experience Code.pptx
Cracking the Customer Experience Code.pptxCracking the Customer Experience Code.pptx
Cracking the Customer Experience Code.pptx
 
Top Digital Marketing Strategy in 2024.pdf
Top Digital Marketing Strategy in 2024.pdfTop Digital Marketing Strategy in 2024.pdf
Top Digital Marketing Strategy in 2024.pdf
 
NewBase 05 July 2024 Energy News issue - 1736 by Khaled Al Awadi_compresse...
NewBase   05 July 2024  Energy News issue - 1736 by Khaled Al Awadi_compresse...NewBase   05 July 2024  Energy News issue - 1736 by Khaled Al Awadi_compresse...
NewBase 05 July 2024 Energy News issue - 1736 by Khaled Al Awadi_compresse...
 
Importance of Quality Transformations in VUCA World
Importance of Quality Transformations in VUCA WorldImportance of Quality Transformations in VUCA World
Importance of Quality Transformations in VUCA World
 
Best Practices in Negotiation for Business Management Students
Best Practices in Negotiation for Business Management StudentsBest Practices in Negotiation for Business Management Students
Best Practices in Negotiation for Business Management Students
 
brojjeddah Home Services Company in Saudi Arabia
brojjeddah Home Services Company in Saudi Arabiabrojjeddah Home Services Company in Saudi Arabia
brojjeddah Home Services Company in Saudi Arabia
 
TALENT ACQUISITION AND MANAGEMENT LECTURE 2
TALENT ACQUISITION AND MANAGEMENT LECTURE 2TALENT ACQUISITION AND MANAGEMENT LECTURE 2
TALENT ACQUISITION AND MANAGEMENT LECTURE 2
 
What is Venture Client for Startup entrepreneur
What is Venture Client for Startup entrepreneurWhat is Venture Client for Startup entrepreneur
What is Venture Client for Startup entrepreneur
 
Entrepreneurial mindset: An Introduction to Entrepreneurship
Entrepreneurial mindset: An Introduction to EntrepreneurshipEntrepreneurial mindset: An Introduction to Entrepreneurship
Entrepreneurial mindset: An Introduction to Entrepreneurship
 
The-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptx
The-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptxThe-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptx
The-Three-Pillars-of-Doctoral-Research-What-Why-and-How (1).pptx
 
1234567891011121314151617181920212223242
12345678910111213141516171819202122232421234567891011121314151617181920212223242
1234567891011121314151617181920212223242
 
High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...
High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...
High Profile Girls Call Bhubaneswar 🎈🔥000XX00000 🔥💋🎈 Provide Best And Top Gir...
 
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual TrainingpptxYou Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
 
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital  BankingCheslyn Jacobs- TymeBank: Building Consumer Trust in Digital  Banking
Cheslyn Jacobs- TymeBank: Building Consumer Trust in Digital Banking
 
Cryptocurrency KYC Policies: Comparing Binance KYC Bypass with Rivals
Cryptocurrency KYC Policies: Comparing Binance KYC Bypass with RivalsCryptocurrency KYC Policies: Comparing Binance KYC Bypass with Rivals
Cryptocurrency KYC Policies: Comparing Binance KYC Bypass with Rivals
 
Pricing sophistication - auto insurance telematics
Pricing sophistication - auto insurance telematicsPricing sophistication - auto insurance telematics
Pricing sophistication - auto insurance telematics
 
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
KineMaster Diamond APK v7.3.11.32200 (4K HD, No Watermark)
 
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
 
Transforming the Future of Limo Services.pptx
Transforming the Future of Limo Services.pptxTransforming the Future of Limo Services.pptx
Transforming the Future of Limo Services.pptx
 

Antibody drug conjugates for cancer therapy - prospects and challenges htp

  • 1. Huateng Pharma https://en.huatengsci.com Antibody-Drug Conjugates for Cancer Therapy - Prospects and Challenges Antibody-drug conjugates (ADCs) are a rapidly evolving class of anticancer therapeutics consisting of antibodies attached to potent cytotoxic drugs via chemical linkers. The antibodies are designed to target specific antigens (receptors) highly expressed in tumor cells. ADCs provide highly selective drugs to tumors, thus minimizing their systemic exposure and potentially leading to improved therapeutic indices (higher efficacy and fewer adverse effects). Most ADCs follow a similar mechanism of action involving antibody-mediated receptor binding, ADC internalization and subsequent release of payload and cytotoxicity, as shown in Figure 1.The success of ADCs relies on several key factors as belows. 1) Target antigens (e.g. CD30, HER2, CD22, CD33, CD79b, Nectin 4, Trop2, BCMA, CD19) 2) Antibody type (e.g. IgG1, IgG2, IgG4, nanobodies, bispecific antibodies) 3) Payload type (e.g. Monomethyl auristatin E (MMAE), DM4, calicheamycin, DM1, MMAF) 4) Linker type (e.g. valine-citrulline, Sulfo-SPDB, hydrazone linker) 5) Conjugation platform (e.g. lysine-, cysteine- and site-specific conjugation) 6) Target indications (e.g. breast cancer, lymphoma, leukemia, uroepithelial cancer, lung cancer, ovarian cancer). ADCs mechanism of action, image source: reference 1
  • 2. Huateng Pharma https://en.huatengsci.com FDA Approved ADCs To date, 11 ADCs have been approved by the FDA, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Lumoxiti®, Polivy®, Padcev®, Enhertu®, Trodelvy®, Blenrep® and Zynlonta™, for oncology indications only (Table 1, Figure 2a). In addition, more than 80 ADCs are currently in clinical studies as single agents or in combination for various tumor types. FDA Approved ADCs, Image source: https://www.biochempeg.com/article/202.html Two of the latest ADCs to be approved, Trodelvy and Zynlonta, were developed with PEG moiety as part of their linker technology to improve solubility and stability in vivo. On April 23, 2021, the FDA approved Zynlonta, the first CD19-targeted ADC, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based on the pivotal Phase II clinical trial LOTIS-2. Zynlonta (loncastuximab tesirine) is a humanized CD19 monoclonal antibody conjugated to pyrrolobenzodiazepine (PBD) dimeric cytotoxin via a linker. PEG linker for Zynlonta: Mal-NH-PEG8-COOH
  • 3. Huateng Pharma https://en.huatengsci.com Structure of Zynlonta On April 22,2020, the FDA approved sacituzumab govitecan (Trodelvy), a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38), for the treatment of some patients with triple-negative breast cancer. PEG linker for Trodelvy: 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid Structure of Trodelvy Novel ADCs in clinical trials More than 80 ADCs are currently in active clinical trials, with the majority in Phase I and Phase I/II (Table 2, Figure 3a). More than 80% of clinical trials are investigating the safety and efficacy of ADCs in a variety of solid tumors, while the remaining trials involve hematologic malignancies (Figure 3b). This may indicate a shift in experimental ADCs in solid tumors in recent years with the early success of T-DM1 and the recent approval of T-Dxd, sacituzumab govitecan, and enfortumab vedotin. In this list, there are about 40 different targets with several ADCs against the same target (Table 2, Figure 3c).
  • 4. Huateng Pharma https://en.huatengsci.com ADCs in clinical trials, image source: reference 1 Challenges in the development of ADCs Why have more not already been approved? The issue of toxicity has been a challenge, as has the complexity of ADCs and the consequent manufacturing challenges. Crafting the right molecule Finding the right targets, proteins, linkers and payloads all belong to the discovery phase. This phase is very challenging because properly defining a drug is key to bringing it successfully to the clinic. ADCs represent an equally highly complex and unpredictable product class. Finding the right target and crafting a potent molecule has proven to be much more difficult than many researchers expected at the start of an ADC study. The initial understanding was that finding a good target antigen for an ADC-based compound required a target that could be rapidly internalized once it reached the cell, with the result that in many cases, targets that were ineffective against monoclonal antibody (mAb) therapies due to rapid internalization became the perfect targets for ADC therapies. Site-specific conjugation
  • 5. Huateng Pharma https://en.huatengsci.com Site-specific conjugation is considered as a second generation ADC conjugation technique. Many ADCs in preclinical and clinical stages are based on site-specific conjugation technology of one form or another. Even though more site-selective ADCs are expected in the future, stochastic conjugation of ADCs can still be successful. Site-selective conjugation does not appear to exhibit significant differences in clinical activity and safety compared to classical non-site-selective conjugation. The lack of commercially available site-specific conjugated molecules is simply a consequence of the head start that stochastic conjugation has had, but it is also possible that the simplicity of manufacturing and the homogeneity of analytical testing methods do not directly lead to better outcomes for patients. Linker chemistry matters Linker chemistry is an important component of ADCs and has a major impact on performance. Linker chemistry plays a key role in in-vivo stability, but was initially assumed to have a passive role with the exception of either being stable or labile in the acidic cytosolic cellular environment. Over the past 20 years, the technology has evolved and matured to the point where linker technology is stable and molecules in development exhibit low levels of de-conjugation in patients. Both protease-cleavable and non-cleavable linkers are in development and on the market. Classical conjugation chemistry approaches include maleimide and hydroxysuccinamide-ester moieties (Seattle Genetics, Roche and Pfizer). There are also a variety of newer linker technologies, some in the proof-of-concept stage and some already in preclinical evaluation. Undesired immune responses ADCs are designed to be more selective than traditional chemotherapeutic agents. The mAb are able to target cancer (or other disease) cells, with payloads delivered with high selectivity and reduced systemic toxicity compared to standard chemotherapeutic agents. Unfortunately, undesired immune responses pose a problem that is difficult to overcome. These responses are largely due to the large number of variables being studied and the relatively small number of clinical trials being conducted. Lower-than-expected therapeutic window The main issue affecting ADC approvals today is that the therapeutic window for these therapies is lower than expected. However, this window has proven to be much more complex than originally hoped, and therefore its clinical impact is
  • 6. Huateng Pharma https://en.huatengsci.com not as great as originally thought. The complexity of ADCs themselves is also a major issue here. Complex supply chain The ADC supply chain is also very complex. ADCs are unique in that they are manufactured as a amalgamation of classical small molecule manufacturing and traditional mAb manufacturing, with the added complexity of high potency drug manufacturing. All three of these characteristics are complex in themselves, and combining them brings the complexity to an even higher level. Supply chain management of ADCs is one of the most complex processes in the pharmaceutical industry and must be managed by experienced teams with the lowest possible risk. As more ADCs are approved commercially, it is believed that a roadmap will be established for other companies to follow, leading to more success in the near future. References: 1. Dean AQ, Luo S, Twomey JD, Zhang B. Targeting cancer with antibody-drug conjugates: Promises and challenges. MAbs. 2021 Jan-Dec;13(1):1951427. doi: 10.1080/19420862.2021.1951427. PMID: 34291723.